Lifesci Capital Has Positive Outlook of DYN FY2025 Earnings

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Analysts at Lifesci Capital boosted their FY2025 earnings estimates for Dyne Therapeutics in a research note issued to investors on Thursday, November 6th. Lifesci Capital analyst F. Brisebois now forecasts that the company will post earnings of ($3.58) per share for the year, up from their previous estimate of ($3.62). Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.44) per share. Lifesci Capital also issued estimates for Dyne Therapeutics’ Q3 2026 earnings at ($0.97) EPS, Q4 2026 earnings at ($0.91) EPS and FY2026 earnings at ($3.63) EPS.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.05.

Several other research analysts have also recently issued reports on the stock. Evercore ISI reissued an “outperform” rating and set a $38.00 target price on shares of Dyne Therapeutics in a research report on Thursday. Raymond James Financial upgraded shares of Dyne Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price objective for the company from $31.00 to $35.00 in a research note on Monday, August 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Wednesday, October 8th. Oppenheimer restated a “market perform” rating and set a $13.00 target price on shares of Dyne Therapeutics in a report on Friday, October 10th. Finally, Chardan Capital dropped their target price on Dyne Therapeutics from $50.00 to $38.00 and set a “buy” rating on the stock in a research report on Tuesday, July 29th. Four analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Dyne Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $34.53.

Dyne Therapeutics Price Performance

DYN opened at $18.36 on Monday. The company has a market capitalization of $2.61 billion, a price-to-earnings ratio of -4.76 and a beta of 1.16. The company has a current ratio of 16.83, a quick ratio of 16.83 and a debt-to-equity ratio of 0.17. Dyne Therapeutics has a 12-month low of $6.36 and a 12-month high of $35.68. The business’s fifty day simple moving average is $15.65 and its 200-day simple moving average is $12.79.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, CEO John Cox sold 2,640 shares of Dyne Therapeutics stock in a transaction on Friday, September 5th. The shares were sold at an average price of $13.41, for a total value of $35,402.40. Following the transaction, the chief executive officer directly owned 199,539 shares of the company’s stock, valued at approximately $2,675,817.99. The trade was a 1.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 14.14% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in DYN. Vanguard Group Inc. grew its holdings in shares of Dyne Therapeutics by 27.6% during the third quarter. Vanguard Group Inc. now owns 9,760,414 shares of the company’s stock valued at $123,469,000 after buying an additional 2,109,257 shares during the last quarter. RA Capital Management L.P. raised its stake in Dyne Therapeutics by 52.2% in the 1st quarter. RA Capital Management L.P. now owns 9,714,392 shares of the company’s stock worth $101,613,000 after acquiring an additional 3,333,248 shares during the last quarter. Atlas Venture Life Science Advisors LLC lifted its position in Dyne Therapeutics by 13.9% during the 1st quarter. Atlas Venture Life Science Advisors LLC now owns 9,130,465 shares of the company’s stock worth $95,505,000 after acquiring an additional 1,111,111 shares during the period. TCG Crossover Management LLC grew its stake in Dyne Therapeutics by 42.1% during the 2nd quarter. TCG Crossover Management LLC now owns 3,766,660 shares of the company’s stock valued at $35,859,000 after purchasing an additional 1,116,510 shares during the last quarter. Finally, Braidwell LP grew its stake in Dyne Therapeutics by 431.6% during the 1st quarter. Braidwell LP now owns 3,621,344 shares of the company’s stock valued at $37,879,000 after purchasing an additional 2,940,162 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.